Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab
May 13, 2024 07:00 ET | Tiziana Life Sciences Ltd.
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Imbria Pharmaceuticals to Present Results from IMPROVE-HCM Trial of Ninerafaxstat in Late-Breaking Clinical Trial Session at American College of Cardiology Annual Scientific Session & Expo (ACC.24)
March 25, 2024 08:00 ET | Imbria Pharmaceuticals Inc.
– Ninerafaxstat Phase 2 clinical trial in non-obstructive hypertrophic cardiomyopathy (nHCM) is complete;Phase 3 to be initiated in the 2H 2024 – BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- Imbria...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
March 13, 2024 07:55 ET | Catalyst Pharmaceuticals, Inc.
AGAMREE® (vamorolone) a Novel Alternative Corticosteroid with Demonstrated Properties in Maintaining Efficacy and a Well-Tolerated Side Effect Profile Available in the U.S. by Prescription for...
US Rare Disease Drug Market Drugs Sales Clinical Trials Insight
July 25, 2023 03:12 ET | KuicK Research
Delhi, July 25, 2023 (GLOBE NEWSWIRE) -- US Orphan Drugs Market, Drugs Sales, Price, Dosage & Clinical Trials Insight 2028 Report Highlights: US Orphan Drugs Market Opportunity: > USD...
logo-01 (3) copy - Copy2.jpg
ConSynance Therapeutics Reports Positive Phase 1 Results for CSTI-500 in Prader-Willi Syndrome Patients
May 30, 2023 10:00 ET | ConSynance Therapeutics
RENSSELAER, New York, May 30, 2023 (GLOBE NEWSWIRE) -- ConSynance Therapeutics, Inc., an emerging biopharmaceutical firm focused on developing novel therapies for rare central nervous system (CNS)...
QSAM Biosciences Receives Rare Pediatric Disease Designation from FDA for CycloSam in the Treatment of Osteosarcoma
February 02, 2022 08:30 ET | QSAM Biosciences Inc.
Austin, TX, Feb. 02, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
Follow one woman as she embarks on a journey of self-discovery in ‘The Royal Orphan’
March 11, 2021 01:39 ET | Archway Publishing
GRABILL, Ind., March 11, 2021 (GLOBE NEWSWIRE) -- An 18-year-old orphan comes to work for her kingdom’s royal family and soon finds romance, personal growth and tragedy in Lanelle Thomas’ new...
Equillium Logo.png
Equillium Granted U.S. FDA Orphan Drug Designations for EQ001 (itolizumab) for both the Prevention and Treatment of Acute Graft-Versus-Host Disease
February 07, 2019 08:08 ET | Equillium
LA JOLLA, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that the...
PledPharma har ansök
PledPharma har ansökt om särläkemedelsstatus (ODD) för Aladote i USA
December 24, 2018 02:00 ET | PledPharma AB
Stockholm, 24 december 2018. PledPharma AB (publ) meddelar att bolaget har lämnat in en ansökan till amerikanska läkemedelsmyndigheten FDA om särläkemedelsstatus (ODD, Orphan Drug Designation) för...
PledPharma applies f
PledPharma applies for an Orphan Drug Designation (ODD) in the US for Aladote
December 24, 2018 02:00 ET | PledPharma AB
Stockholm, December 24, 2018. PledPharma AB (publ) announces that the company has filed an application for an Orphan Drug Designation (ODD) to the US FDA for the drug candidate Aladote®, developed to...